查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004728

月經治療市場：2026-2032年全球市場預測（依治療方法、藥物類別、給藥途徑、通路、應用及最終用戶分類）

Dysmenorrhea Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，月經治療市場價值將達到 85.1 億美元，到 2026 年將成長至 92.4 億美元，到 2032 年將達到 158.3 億美元，複合年成長率為 9.28%。

主要市場統計數據
基準年 2025 85.1億美元
預計年份：2026年 92.4億美元
預測年份 2032 158.3億美元
複合年成長率 (%) 9.28%

引人入勝的引言，闡述了月經的治療選擇、臨床重點、病人期望以及影響醫療保健服務的機構因素。

月經仍然是一個普遍存在的臨床問題，促使人們自我護理尋求醫療保健服務、加強患者自我護理，並推動治療和非治療性介入的多樣化。女性和醫療保健專業人員面臨著許多選擇，包括非處方藥、荷爾蒙避孕藥、輔助療法以及日益增加的醫療設備和數位輔助工具。因此，臨床實踐、藥品分銷和產品開發領域的相關人員必須攜手合作，收集證據、傳遞訊息並協調獲取管道，以滿足患者需求和支付方的期望。

以證據為基礎，概述了臨床、技術和報銷方面的變化如何重塑月經的治療方法和患者照護。

目前，月經治療正經歷多項變革，這些變革影響著治療方法的研發、臨床實踐以及病患的行為。其中最顯著的變化之一是，非藥物療法與傳統藥物療法並存的趨勢日益明顯。患者和臨床醫生越來越願意將針灸、結構化運動方案、營養補充劑和局部熱療納入治療計劃，這反映出疼痛管理正朝著多方面綜合的方向發展。這種整合的驅動力源自於患者對副作用較少的治療方法的偏好，以及醫療專業人員為存在標準療法禁忌症的患者尋求輔助治療方案的需求。

重點分析 2025 年以後的關稅政策如何重塑月經治療藥物整個供應鏈的採購、製造和分銷策略。

政策環境的複雜性加劇了月經治療相關相關人員的困境。特別是，美國將於2025年實施的關稅措施，正對整個供應鏈和成本結構產生連鎖反應。這些貿易相關措施影響藥物活性成分、用於熱療和神經調節療法的醫療設備以及某些營養補充劑生產原料的採購和定價。因此，擁有全球供應鏈的製造商正在重新審視其籌資策略，並加快考慮將生產遷回國內，並尋求替代供應商以減輕關稅相關成本波動的影響。

一個綜合細分框架，闡明了治療方法、給藥方法、通路、臨床應用和最終用戶方面的差異，並有助於制定商業化策略。

了解市場區隔對於使產品開發和商業化策略與臨床實踐和患者偏好相契合至關重要。按治療方法類型進行分析時，非藥理學的處置方法和藥物療法之間存在著明顯的二分法。非藥物療法包括針灸、營養補充品、運動療法和熱療。在營養補充品領域，醫療保健專業人員和消費者會區分草藥萃取物、 Omega-3補充劑和維生素補充劑。鑑於這兩種途徑並存的現實情況，產品開發人員必須清楚地展現差異化的價值提案。藥物通常強調可衡量的症狀緩解和標準化劑量，而非藥物產品則利用其安全性、便利性和患者感知到的健康益處作為其競爭優勢。

對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、支付方趨勢、監管預期和患者偏好進行區域評估。

月經治療的區域趨勢凸顯了不同地區的優先事項和法規環境的差異，這些因素影響治療方案的採納、證據標準和患者就醫途徑。在美洲，儘管藥物治療應用廣泛，但消費者對非藥物輔助治療的需求也在不斷成長，這得益於蓬勃發展的零售藥局管道和日益完善的遠距遠端醫療服務。由於各地區的報銷框架和支付方行為各不相同，製造商不得不根據地區調整定價和證據策略。臨床實踐指南和患者權益倡導組織影響著醫生的處方行為，並推動了臨床有效的替代療法（而非傳統鎮痛藥）的快速普及。

對企業環境進行簡要分析，重點關注跨國製藥公司、學名藥生產商、女性健康專家和醫療保健創新公司的角色。

月經市場呈現多元化的格局，既有成熟的製藥公司，也有學名藥生產商、女性健康專家和醫療創新企業。大型跨國製藥公司憑藉其廣泛的業務基礎以及與支付方和醫療服務提供者建立的穩固關係，大力推廣品牌止痛藥和避孕產品。同時，學名藥生產商則確保在許多市場提供價格親民的替代選擇。此外，女性健康專家在生殖醫學和病人參與擁有豐富的專業知識，能夠推廣差異化的避孕產品並進行有針對性的宣傳宣傳活動。

產業領導者可採取的策略重點：產生證據、供應鏈韌性、綜合護理夥伴關係和分段商業化。

產業領導者應優先考慮如何將臨床證據的產生與便利的分發系統和以病人為中心的參與模式結合。首先，他們需要投資可操作的臨床試驗和真實世界證據研究，以收集患者報告的結果、功能指標以及與藥物和非藥物療法相比的療效。這些數據對於說服支付方、臨床醫生和指南委員會至關重要，同時也指南制定吸引患者的有效訊息，幫助他們實際改善日常生活功能。

我們透過透明的混合方法，結合專家訪談、文獻整合、監管分析和資料檢驗驗證，確保獲得穩健且可操作的見解。

本研究採用混合研究方法，結合質性專家訪談、系統性文獻回顧、監理文件分析、二手資訊整合，以獲得可靠的見解。主要研究包括對臨床醫生、藥劑師、支付方代表和產品開發經理進行結構化訪談，以檢驗臨床路徑、產品應用促進因素和未滿足的需求。二手研究則涉及對已發布的臨床指南、同行評審的臨床研究、監管指導文件以及公開的企業資訊披露進行審查，以驗證研究結論並識別新興趨勢。

以循證差異化、供應鏈韌性、本地化適應和以患者為中心的護理路徑為重點的綜合分析得出結論。

這項綜合分析凸顯了月經治療領域的一個轉捩點：傳統藥物療法正與非藥物輔助療法和數位化解決方案相結合，以滿足不斷變化的患者需求。投資於嚴謹的實證醫學研究、穩健的供應鏈以及整合式醫療夥伴關係的相關人員將更有利於獲得臨床和商業性價值。同時，關稅和區域政策差異導致的供應鏈中斷，要求積極的風險管理措施和因地制宜的市場策略，以避免供應中斷和價格壓力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法分類的經痛治療市場

  • 非藥物療法
    • 針刺
    • 營養補充品
      • 草藥萃取物
      • Omega-3補充劑
      • 維生素補充劑
    • 運動療法
    • 熱療
  • 藥物治療

第9章：月經治療市場：依藥物類別分類

  • 荷爾蒙避孕藥
  • NSAIDs

第10章：月經治療市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用

第11章：經月經治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：經痛治療市場：依應用領域分類

  • 原發性經痛
  • 續發性月經

第13章：月經治療市場：依最終使用者分類

  • 診所
  • 居家照護
  • 醫院
  • 專業醫療中心
    • 健身中心
    • 婦科診所

第14章：經月經治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：經月經治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：經月經治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國月經治療市場

第18章：中國經痛月經市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc（GSK）
  • Haleon Plc
  • Himalaya Wellness Co.
  • Johnson & Johnson
  • Lupin
  • Novartis International AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-742BD517DA92

The Dysmenorrhea Treatment Market was valued at USD 8.51 billion in 2025 and is projected to grow to USD 9.24 billion in 2026, with a CAGR of 9.28%, reaching USD 15.83 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.51 billion
Estimated Year [2026] USD 9.24 billion
Forecast Year [2032] USD 15.83 billion
CAGR (%) 9.28%

A compelling introductory framing that situates dysmenorrhea treatment choices, clinical priorities, patient expectations, and systemic forces shaping care delivery

Dysmenorrhea remains a pervasive clinical concern that drives healthcare utilization, consumer self-care, and an expanding mix of therapeutic and non-therapeutic interventions. Women and healthcare providers navigate a complex set of choices that include over-the-counter analgesics, hormonal contraceptives, complementary therapies, and an increasing array of device-based or digital adjuncts. As a result, stakeholders across clinical practice, pharmacy distribution, and product development must coordinate evidence generation, messaging, and access pathways to meet patient needs and payer expectations.

Clinical priorities have shifted toward personalized pain management that balances efficacy, tolerability, reproductive planning, and long-term safety. Patients are more informed and expect treatment pathways that address both acute symptom relief and underlying contributors to recurrent pain. Meanwhile, regulatory agencies and payers are demanding clearer clinical endpoints and real-world effectiveness data to support reimbursement and labeling claims. These forces are converging with broader healthcare trends-such as telehealth, direct-to-consumer distribution, and increased demand for non-pharmacological options-to reshape how dysmenorrhea care is developed, delivered, and scaled.

Consequently, manufacturers, clinicians, and policy stakeholders must align clinical evidence strategies with distribution and patient engagement models. This alignment requires cross-functional planning that integrates clinical trial design, comparative effectiveness research, digital engagement metrics, and supply chain resilience. Taken together, such an integrated approach can improve patient outcomes while creating differentiated market positions for therapies and care models that demonstrate meaningful value beyond symptom suppression.

An evidence-focused overview of the clinical, technological, and reimbursement shifts that are reshaping dysmenorrhea treatment approaches and patient care

The landscape for dysmenorrhea treatment is undergoing several transformative shifts that affect therapeutic development, clinical practice, and patient behavior. One of the most consequential shifts is the mainstreaming of non-pharmacological approaches alongside conventional drug therapies. Patients and clinicians are increasingly open to integrating acupuncture, structured exercise programs, dietary supplements, and targeted heat therapy into care plans, reflecting a broader move toward multimodal pain management. This integration is driven by patient preference for lower side-effect profiles and by practitioners seeking complementary options for those with contraindications to standard therapies.

Concurrently, digital health solutions and wearable technologies are altering the patient experience. Mobile symptom tracking, telemedicine consultations, and digitally enabled adherence tools allow for more nuanced monitoring of treatment response and lifestyle factors. Such capabilities support more individualized therapy adjustments and create opportunities for outcome-based care models. Additionally, innovation in topical formulations and localized delivery systems is enabling faster onset of symptom relief with fewer systemic effects, which appeals to patients prioritizing rapid and targeted outcomes.

Regulatory and reimbursement environments are also shifting, emphasizing real-world evidence and patient-reported outcomes in value assessments. Pharmaceutical and device developers must therefore invest in pragmatic clinical trials and longitudinal outcome studies to demonstrate utility across diverse populations. Taken together, these transformative shifts underscore a market moving from one-size-fits-all approaches toward individualized, evidence-backed care pathways that combine pharmacological and non-pharmacological modalities to meet evolving patient and payer expectations.

A focused analysis of how post-2025 tariff policies have reshaped sourcing, manufacturing, and distribution strategies across dysmenorrhea treatment supply chains

The policy environment has introduced a layer of complexity for stakeholders in dysmenorrhea treatment, particularly as tariff measures enacted in the United States in 2025 have had cascading effects across supply chains and cost structures. These trade-related measures have influenced the sourcing and pricing of active pharmaceutical ingredients, medical devices used for heat therapy and neuromodulation, and certain raw materials for dietary supplement manufacturing. As a result, manufacturers with global supply chains have re-evaluated sourcing strategies, accelerated reshoring considerations, and sought alternative suppliers to mitigate exposure to tariff-related cost volatility.

In practical terms, the cumulative impact has been most visible in procurement and contracting decisions. Healthcare providers and distributors are increasingly prioritizing supplier diversification and entering longer-term agreements to stabilize unit costs. Contract manufacturers have seen heightened demand for cost transparency and tariff pass-through analyses as pharmaceutical firms attempt to preserve affordability for end users without compromising margins. At the same time, companies with vertically integrated supply chains or near-shore manufacturing capabilities have found strategic advantages in maintaining competitive pricing and ensuring continuity of supply.

Policy uncertainty has also incentivized investment in tariff-sensitive risk management, including hedging strategies, inventory buffering, and increased use of free trade agreements where available. For innovators and smaller firms, the added complexity can create barriers to market entry or slow commercialization timelines unless they secure distribution partnerships or localized manufacturing arrangements. Overall, the tariff-driven adjustments underline the importance of evaluating geopolitical and trade policy risks when planning product launches and channel strategies for dysmenorrhea therapies and adjunctive devices.

An integrated segmentation framework that clarifies therapeutic, delivery, channel, clinical application, and end-user distinctions to inform commercialization tactics

Understanding segmentation is essential for aligning product development and commercialization strategies with clinical practice and patient preferences. When treatments are considered by type, there is a clear bifurcation between non-pharmacological and pharmacological approaches; non-pharmacological modalities include acupuncture therapy, dietary supplements, exercise therapy, and heat therapy, and within dietary supplements practitioners and consumers distinguish between herbal extracts, omega-3 supplements, and vitamin supplements. This dual-pathway reality means that product developers must articulate differentiated value propositions: pharmacological agents typically emphasize measurable symptom reduction and standardized dosing, while non-pharmacological offerings compete on safety profile, convenience, and patient-perceived wellness benefits.

Looking at drug class segmentation, hormonal contraceptives and nonsteroidal anti-inflammatory drugs represent two principal therapeutic families, each serving different clinical objectives and patient populations. Hormonal contraceptives are often selected for patients seeking both cycle regulation and long-term control of cramping, whereas NSAIDs remain the frontline choice for acute pain relief due to their established efficacy profile. Route of administration also influences adoption dynamics: injectable, oral, and topical delivery formats create distinct adherence patterns and tolerability considerations that inform prescribing choices and product positioning.

Distribution channels further shape access and patient behavior, with hospital pharmacies, online pharmacies, and community pharmacies each offering unique advantages around immediacy, counseling, and convenience. Application-based segmentation between primary and secondary dysmenorrhea affects clinical pathway design and evidence requirements, while end-user segmentation across clinics, home care, hospitals, and specialty centers-with specialty centers encompassing fitness centers and gynecological clinics-highlights diverse points of care and potential partnership opportunities. Together, these layered segmentation dimensions enable companies to prioritize target populations, tailor messaging, and design evidence-generation programs that align with how therapies will be used in real-world settings.

A regionally differentiated assessment of clinical practice, payer dynamics, regulatory expectations, and patient preferences across the Americas, EMEA, and Asia-Pacific

Regional dynamics in dysmenorrhea treatment reveal differentiated priorities and regulatory contexts that affect adoption, evidence standards, and patient access. In the Americas, there is strong uptake of both pharmacological treatments and a growing consumer demand for complementary non-pharmacological options, supported by robust retail pharmacy channels and expanding telehealth services. Reimbursement frameworks and payer behavior vary by jurisdiction, prompting manufacturers to adapt pricing and evidence strategies regionally. Clinical practice guidelines and patient advocacy influence prescriber habits and rapid adoption of clinically validated alternatives to traditional analgesics.

The Europe, Middle East & Africa region presents a heterogeneous landscape with diverse regulatory regimes and healthcare financing models. In several European markets, higher regulatory scrutiny and established guideline-driven care pathways prioritize high-quality clinical data and long-term safety evidence. Meanwhile, certain markets within the Middle East and Africa emphasize affordability and accessibility, which favors low-cost generics and scalable non-pharmacological interventions. Payer fragmentation and variable diagnostic coding practices require localized market access strategies and partnerships with regional distributors and clinical centers.

In Asia-Pacific, demographic trends, rising healthcare spending, and rapid digital adoption are accelerating demand for a broad spectrum of treatment options, including technologically enabled devices and telehealth-enabled care models. Regulatory harmonization efforts and expanding clinical research infrastructure support faster evidence generation, while culturally specific preferences guide the acceptance of complementary therapies. Across all regions, manufacturers must balance global development plans with tailored local execution to address regulatory requirements, distribution realities, and patient expectations effectively.

A concise corporate landscape analysis that highlights the roles of multinational pharmaceutical firms, generics manufacturers, women's health specialists, and medtech innovators

Corporate behavior across the dysmenorrhea landscape reflects a mix of established pharmaceutical players, generics manufacturers, specialist women's health firms, and medtech innovators. Large multinational drug companies leverage broad commercial footprints and established relationships with payers and providers to support branded analgesics and contraceptive solutions, while generics manufacturers ensure widespread availability of cost-sensitive options in many markets. At the same time, specialized firms focused on women's health bring concentrated expertise in reproductive therapeutics and patient engagement, positioning them to advance differentiated contraceptive formulations and targeted education campaigns.

Medtech and digital health entrants are reshaping the competitive set by introducing device-based pain relief and symptom-tracking platforms that complement pharmacological care. These entrants often pursue partnerships with clinical networks and consumer distribution channels to accelerate adoption and gather real-world usage data. Contract manufacturers and companies with localized production capabilities have become strategically important in the wake of trade and tariff pressures, enabling more predictable supply and improved cost competitiveness. Across the ecosystem, cross-sector collaborations-between pharma, device makers, and digital health providers-are emerging as a primary vehicle for delivering comprehensive, multimodal care pathways that meet the broader needs of patients and providers.

Actionable strategic priorities for industry leaders focused on evidence generation, supply chain resilience, integrated care partnerships, and segmented commercialization

Industry leaders should prioritize initiatives that align clinical evidence generation with accessible distribution and patient-centered engagement models. First, invest in pragmatic clinical trials and real-world evidence studies that capture patient-reported outcomes, functional measures, and comparative effectiveness against both pharmacological and non-pharmacological alternatives. These data will be essential to persuade payers, clinicians, and guideline committees, while also informing messaging that resonates with patients seeking tangible improvements in daily functioning.

Second, diversify supply chains and manufacturing footprints to reduce exposure to tariff and trade policy risk. Near-shoring, multi-sourcing of active ingredients, and deeper collaboration with contract manufacturers can stabilize costs and ensure continuity during geopolitical or policy disruptions. Third, build partnerships across clinical, digital, and retail ecosystems to create integrated care pathways; for example, linking prescribed therapies with digital symptom tracking or heat therapy devices can enhance adherence and provide valuable outcome data.

Finally, tailor go-to-market strategies by combining segmented clinical messaging with channel-specific distribution tactics. For populations prioritizing rapid onset of relief, emphasize topical or fast-acting formulations; for patients focused on long-term control and reproductive planning, highlight hormonal options backed by robust safety data. By executing on these priorities, leaders can accelerate adoption, improve patient satisfaction, and mitigate commercial risks associated with supply chain and policy volatility.

A transparent mixed-methods research approach combining expert interviews, literature synthesis, regulatory analysis, and data triangulation to ensure robust and actionable findings

This study applies a mixed-methods research approach integrating qualitative expert interviews, systematic literature review, regulatory document analysis, and synthesis of secondary public-domain sources to produce robust insights. Primary research includes structured consultations with clinicians, pharmacists, payer representatives, and product development leaders to validate clinical pathways, adoption drivers, and unmet needs. Secondary research canvassed published clinical guidelines, peer-reviewed clinical studies, regulatory guidance documents, and publicly available corporate disclosures to cross-check claims and identify emerging trends.

Data triangulation was used to reconcile differences between stakeholder perspectives and published evidence, and findings were vetted through iterative peer review by subject-matter experts. Segmentation logic was applied across treatment type, drug class, route of administration, distribution channel, clinical application, and end user to ensure that insights map directly to practical commercial and clinical decision points. Limitations include variability in regional data granularity and evolving policy developments that may shift the context after the study's cut-off date; these were mitigated by sensitivity analyses and by capturing a range of expert viewpoints.

Ethical research practices were observed throughout, with all primary interview participants consenting to attribution-free use of insights and confidential information handled under agreed terms. The methodology emphasizes transparency, reproducibility, and pragmatic relevance to inform strategy development and operational planning within the dysmenorrhea treatment ecosystem.

A concluding synthesis that emphasizes evidence-driven differentiation, supply chain resilience, regional adaptation, and patient-centered care pathways

The cumulative analysis underscores an inflection point in dysmenorrhea care where traditional pharmacological strategies are integrating with complementary non-pharmacological modalities and digitally enabled solutions to meet evolving patient needs. Stakeholders who invest in rigorous evidence generation, resilient supply chains, and integrated care partnerships will be best positioned to capture clinical and commercial value. At the same time, tariff-driven supply chain disruptions and heterogeneous regional policies require proactive risk management and localized market strategies to avoid interruption and pricing pressures.

Clinicians and payers alike are increasingly focused on outcomes that matter to patients, including functional improvement and quality-of-life measures, which shifts the burden of proof toward longitudinal and pragmatic evidence rather than short-term symptom metrics alone. For innovators, the path to differentiation lies in demonstrating not only clinical efficacy but also improved daily functioning, safety, and convenience across real-world settings. Ultimately, the most successful approaches will be those that combine rigorous clinical evidence with thoughtful distribution design and patient-centered engagement to deliver sustainable improvements in care and access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dysmenorrhea Treatment Market, by Treatment Type

  • 8.1. Non Pharmacological
    • 8.1.1. Acupuncture Therapy
    • 8.1.2. Dietary Supplements
      • 8.1.2.1. Herbal Extracts
      • 8.1.2.2. Omega 3 Supplements
      • 8.1.2.3. Vitamin Supplements
    • 8.1.3. Exercise Therapy
    • 8.1.4. Heat Therapy
  • 8.2. Pharmacological

9. Dysmenorrhea Treatment Market, by Drug Class

  • 9.1. Hormonal Contraceptives
  • 9.2. Nsaids

10. Dysmenorrhea Treatment Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Dysmenorrhea Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Dysmenorrhea Treatment Market, by Application

  • 12.1. Primary Dysmenorrhea
  • 12.2. Secondary Dysmenorrhea

13. Dysmenorrhea Treatment Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals
  • 13.4. Specialty Centers
    • 13.4.1. Fitness Centers
    • 13.4.2. Gynecological Clinics

14. Dysmenorrhea Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Dysmenorrhea Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Dysmenorrhea Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Dysmenorrhea Treatment Market

18. China Dysmenorrhea Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. AbbVie Inc.
  • 19.7. Astellas Pharma
  • 19.8. AstraZeneca
  • 19.9. Bayer AG
  • 19.10. Boehringer Ingelheim
  • 19.11. Cipla Inc.
  • 19.12. Dr. Reddy's Laboratories Ltd.
  • 19.13. GlaxoSmithKline plc (GSK)
  • 19.14. Haleon Plc
  • 19.15. Himalaya Wellness Co.
  • 19.16. Johnson & Johnson
  • 19.17. Lupin
  • 19.18. Novartis International AG
  • 19.19. Perrigo Company plc
  • 19.20. Pfizer Inc.
  • 19.21. Reckitt Benckiser Group PLC.
  • 19.22. Sanofi S.A.
  • 19.23. Sun Pharmaceutical Industries Ltd.
  • 19.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ACUPUNCTURE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ACUPUNCTURE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ACUPUNCTURE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OMEGA 3 SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OMEGA 3 SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OMEGA 3 SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HEAT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HEAT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HEAT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HORMONAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HORMONAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HORMONAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY FITNESS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY FITNESS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY FITNESS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GYNECOLOGICAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GYNECOLOGICAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GYNECOLOGICAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 221. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)